drugset / Trial / NCT05180097
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2
Recruiting
84 enrolled
Canadian Cancer Trials Group
Australasian Leukaemia and Lymphoma Group · collabMerck Sharp & Dohme LLC · collabPfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Comparator | Dexamethasone | Small molecule | 40 mg | Oral |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |